This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Yon Su Kim, Seoul National University Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Yon Su Kim, Seoul National University Hospital Identifier:
First received: January 13, 2012
Last updated: April 9, 2012
Last verified: April 2012

Proteinuria is not only a marker of chronic kidney disease (CKD) progression, but also a marker of cardiovascular disease and death. In previous studies, active vitamin D deficiency is associated with cardiovascular risk factors such as albuminuria, diabetes mellitus, and lower glomerular filtration rate (GFR). And calcitriol was shown to have a preventive effect in progressive glomerular damage in a renal ablation model. Calcitriol, an active form of vitamin D (1,25-dihydroxyvitamin-D3), is commonly used for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney diseases.

Therefore, the objective of this study is to evaluate the anti-proteinuric effect of calcitriol in non-diabetic kidney disease patients. They will be treated with calcitriol and placebo for 24 weeks and observed for 24 weeks after treatment. Proteinuria, renal function, serum and urinary inflammatory markers, and adverse event will be monitored.

Condition Intervention Phase
Proteinuria Drug: Calcitriol Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients

Resource links provided by NLM:

Further study details as provided by Yon Su Kim, Seoul National University Hospital:

Primary Outcome Measures:
  • Changes in proteinuria [ Time Frame: 6, 12 months after administration ]
    Comparison of proteinuria amount checked by random urine protein/creatinine ratio

Secondary Outcome Measures:
  • Changes in renal function [ Time Frame: 3, 6, 9 and 12 months ]
    Comparison of in serum creatinine level from baseline

  • Changes in urinary renal damage markers [ Time Frame: 6, 12 months ]
    Comparison of urinary TGF-beta, TNF-alpha, MCP-1 level from baseline

Estimated Enrollment: 240
Study Start Date: January 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Calcitriol Drug: Calcitriol
Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Other Name: Calcio® (Hanmi Pharm Co., Korea)
No Intervention: Placebo Drug: Placebo
Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months


Ages Eligible for Study:   19 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Nondiabetic kidney disease patients aged 19-70 years
  • MDRD GFR ≥ 30 mL/min/1.73m2
  • Patients with residual urine protein/creatinine ratio > 200 mg/g
  • Adequate blood pressure control as treated systolic blood pressure <=140 or diastolic <=90 mmHg with RAS inhibitor for more than 3 months
  • Normotensive patients untreated with RAS inhibitors
  • Serum intact PTH as 35-500 mg/dL and serum calcium less than 10.2 mg/dL
  • Patients who have not been treated vitamin D within the 3 months prior to signing the informed consent form

Exclusion Criteria:

  • Patients with nephrotic-range proteinuria (24 hour urine protein >3.5 g/24 hr)
  • Patients with rapidly progressive glomerulonephritis
  • Patients requiring renal replacement therapy immediately
  • Hypercalcemia (uncorrected serum calcium level > 10.2 mg/dL) within 3 months
  • Malignant hypertension
  • Heart failure (New York Heart Association [NYHA] functional class II to IV or LVEF less than 40%)
  • Severe chronic obstructive lung disease
  • Decompensated liver disease
  • Known allergy or hypersensitivity to vitamin D
  • Current treatment with steroids and/or immunosuppressive agents
  • No other active primary malignancy requiring treatment or that limits survival to ≤ 2 years
  • History of noncompliance to medical regimen
  • Inability to give an informed consent or to cooperate with researchers (e.g., psychiatric disorder)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01512862

Contact: Nayoung Han, M.S. +82-2-2072-0335

Korea, Republic of
Seoul National University Bundang Hospital Enrolling by invitation
Seongnam, Gyeonggi-do, Korea, Republic of, 463-707
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Yon Su Kim, M.D., Ph.D.    82-2-2072-2264   
Contact: Dong Ki Kim, M.D., Ph.D.    82-2-2072-2303   
Principal Investigator: Yon Su Kim, M.D., Ph.D.         
Sub-Investigator: Dong Ki Kim, M.D., Ph.D.         
Sub-Investigator: Nayoung Han, M.S.         
SMG-SNU Boramae Medical Center Enrolling by invitation
Seoul, Korea, Republic of, 156-707
Sponsors and Collaborators
Seoul National University Hospital
Study Chair: Jung Mi Oh, Pharm.D. Seoul National Univerisy College of Pharmacy
Principal Investigator: Yon Su Kim, M.D., Ph.D. Seoul National University Hospital
  More Information

Responsible Party: Yon Su Kim, Professor, Seoul National University Hospital Identifier: NCT01512862     History of Changes
Other Study ID Numbers: SNUH-CCTO
Study First Received: January 13, 2012
Last Updated: April 9, 2012

Keywords provided by Yon Su Kim, Seoul National University Hospital:

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 25, 2017